ALXN - Alexion Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
107.78
-3.96 (-3.54%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close111.74
Open111.85
Bid107.78 x 100
Ask107.89 x 100
Day's Range102.10 - 111.85
52 Week Range96.18 - 149.34
Volume5,038,527
Avg. Volume2,169,506
Market Cap23.966B
Beta1.07
PE Ratio (TTM)54.71
EPS (TTM)1.97
Earnings DateApr 26, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est158.60
Trade prices are not sourced from all markets
  • Alexion Slips On Reports Brazil Will Allow Copycats Of Blockbuster Soliris
    Investor's Business Daily20 hours ago

    Alexion Slips On Reports Brazil Will Allow Copycats Of Blockbuster Soliris

    Alexion slid to a 10-month low Friday after reports emerged that Brazil's government will allow drugmakers to produce biologic copies of Alexion's blockbuster drug Soliris.

  • Business Wire21 hours ago

    Alexion Provides Statement on Superior Court of Justice (STJ) Decision in Brazil Involving Soliris® (Eculizumab)

    Recent media reports have incorrectly stated that the Brazilian Superior Court of Justice has granted a compulsory license of Soliris® (eculizumab). Alexion would like to clarify that no compulsory license of Soliris® was requested or granted in Brazil.

  • Benzingayesterday

    The Week Ahead In Biotech: PDUFA Dates, IPOs And More

    The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) is almost flat for the week after adding about 5 percent in the week ended April 13. Will the following catalytic events lead to a resumption ...

  • Biotech Stock Roundup: ALKS Up, CLDX Down, ALXN to Acquire Wilson Therapeutics
    Zacks3 days ago

    Biotech Stock Roundup: ALKS Up, CLDX Down, ALXN to Acquire Wilson Therapeutics

    The biotech space was a witness to a series of events. while share price of several stocks moved up, a few fell substantially.

  • Pharma M&A Active This Week: 4 Potential Buyout Targets
    Zacks8 days ago

    Pharma M&A Active This Week: 4 Potential Buyout Targets

    Novartis and Alexion announce respective acquisitions of AveXis and Wilson Therapeutics for a pipeline boost. We suggest four stocks as hot acquisition picks this year.

  • Alexion: Analysts Raise Their Target Prices
    Market Realist8 days ago

    Alexion: Analysts Raise Their Target Prices

    Alexion Pharmaceuticals (ALXN) is one of the leading biotechnology firms. Soliris is approved to treat aHUS (atypical hemolytic uremic syndrome) and PHN (paroxysmal nocturnal hemoglobinuria). Alexion’s latest acquisition of Wilson Therapeutics is a turnaround strategy that’s being implemented to restructure Alexion’s performance and investors’ sentiments in the market.

  • WTX101: A Superior Treatment for Wilson Disease
    Market Realist8 days ago

    WTX101: A Superior Treatment for Wilson Disease

    On April 11, 2018, Alexion Pharmaceuticals (ALXN) announced the acquisition of Wilson Therapeutics, which is developing a “first-of-its-kind” treatment for Wilson disease. Currently, Wilson disease is treated with copper chelators, Penicillamine or Trientine, to remove copper from serum. The drug has the potential to become the standard of care for Wilson disease patients.

  • Wilson Disease: A Market Opportunity for Alexion
    Market Realist8 days ago

    Wilson Disease: A Market Opportunity for Alexion

    On April 11, 2018, Alexion Pharmaceuticals (ALXN) announced the acquisition of Wilson Therapeutics. Wilson Therapeutics is developing a drug to treat Wilson disease. Wilson disease is a rare genetic disorder that’s potentially life-threatening.

  • Strategic Rationale behind Alexion’s Acquisition
    Market Realist8 days ago

    Strategic Rationale behind Alexion’s Acquisition

    Wilson Therapeutics is a biopharmaceutical company focused on developing rare disease therapies. The company is listed on the Nasdaq Stockholm Exchange and has a market capitalization of 6.5 billion Swedish kronor. Wilson Therapeutics is developing a novel therapy to treat Wilson disease, which is a rare genetic and chronic disorder characterized by an accumulation of copper in the brain, liver, and other vital organs.

  • Alexion to Acquire Wilson Therapeutics for $855 Million
    Market Realist8 days ago

    Alexion to Acquire Wilson Therapeutics for $855 Million

    On April 11, 2018, Alexion Pharmaceuticals (ALXN) announced that it has made a public cash offer to Wilson Therapeutics’ shareholders to acquire all of the company’s outstanding shares. Wilson Therapeutics is a Sweden-based biopharmaceuticals firm. The acquisition will advance Alexion’s long-term growth strategy, which consists of advancing and rebuilding its rare disease pipeline. Alexion aims to accelerate the diversification of its product portfolio.

  • ACCESSWIRE8 days ago

    Blog Exposure - Alexion Pharma to Acquire Swedish Biotech Wilson Therapeutics

    Stock Monitor: Argos Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 13, 2018 / Active-Investors.com has just released a free research report on Alexion Pharma, Inc. (NASDAQ: ALXN ...

  • Alexion (ALXN) to Acquire Wilson Therapeutics for $855M
    Zacks9 days ago

    Alexion (ALXN) to Acquire Wilson Therapeutics for $855M

    Alexion (ALXN) announces that the company will acquire Sweden-based Wilson Therapeutics for $855 million, the latest company to join the ongoing acquisitions spree in the biotech sector.

  • Business Wire9 days ago

    Alexion to Report First Quarter 2018 Results on Thursday, April 26, 2018

    Alexion Pharmaceuticals, Inc. today announced that the Company will report its financial results for the first quarter ended March 31, 2018 on Thursday, April 26, 2018 before the US financial markets open.

  • How Alexion Could Diversify From Its Cash Cow To Battle Valeant, Teva
    Investor's Business Daily10 days ago

    How Alexion Could Diversify From Its Cash Cow To Battle Valeant, Teva

    Alexion Pharmaceuticals will snap up Wilson Therapeutics in a move that helps it diversify from its blockbuster franchise and compete with Valeant and Teva.

  • Jakafi Continues to Be Strong Growth Driver for Incyte in 2018
    Market Realist10 days ago

    Jakafi Continues to Be Strong Growth Driver for Incyte in 2018

    Incyte has projected Jakafi’s GAAP (generally accepted accounting principles) and non-GAAP revenues for full-year 2018 to fall in the range of $1.35 billion to $1.4 billion. This revenue performance could be driven by an anticipated rise in demand for the drug in existing rare blood cancer indications of myelofibrosis (or MF) and polycythemia vera (or PV) as well as from potential new indications such as graft versus host disease (or GVHD) and essential-thrombocythemia (or ET). Jakafi has been granted orphan drug designation in MF, PV, ET, GVHD, and acute lymphoblastic leukemia (ALL) indications.

  • Barrons.com10 days ago

    Vertex Is Worth More Than You Think

    Shares of  Vertex Pharmaceuticals (VRTX) have easily outrun the market year-to-date, rising 8%, and the drug maker has notched returns of more than 42% in the past year. Analyst Hartaj Singh reiterated an Outperform rating and $190 price target on the shares Wednesday, but notes that Vertex could see as much as 50% upside to that target, which would put the shares at $285.

  • Reuters10 days ago

    Biotech M&A rolls on as Alexion snaps up Wilson for $855 mln

    Alexion Pharmaceuticals has agreed to buy Sweden's Wilson Therapeutics for 7.1 billion Swedish crowns ($855 million), boosting its line-up of rare disease drugs as a wave of deal-making in the biotechnology sector continues. Alexion was one of the stars of the biotech sector in the first half of this decade, but it has stumbled more recently following an exodus of top management and a sales practices scandal related to Soliris, its pricey rare disease treatment.

  • Why Alexion Pharmaceuticals Inc (NASDAQ:ALXN) May Not Be As Efficient As Its Industry
    Simply Wall St.10 days ago

    Why Alexion Pharmaceuticals Inc (NASDAQ:ALXN) May Not Be As Efficient As Its Industry

    Alexion Pharmaceuticals Inc (NASDAQ:ALXN) generated a below-average return on equity of 4.98% in the past 12 months, while its industry returned 17.87%. An investor may attribute an inferior ROE toRead More...

  • Reuters10 days ago

    Alexion to buy Swedish biotech Wilson Therapeutics for $855 mln

    Alexion Pharmaceuticals said on Wednesday it had agreed to buy Sweden's Wilson Therapeutics for 7.1 billion Swedish crowns to boost its line-up of rare disease drugs. The U.S. group is acquiring the business ...

  • The Wall Street Journal10 days ago

    [$$] Alexion Makes Bid for Sweden's Wilson Therapeutics

    Alexion Pharmaceuticals has made a $788 million bid for Swedish biopharmaceutical company Wilson Therapeutics as it looks to bolster its portfolio of treatments for rare disorders.

  • Business Wire10 days ago

    Alexion to Acquire Wilson Therapeutics

    Alexion Pharmaceuticals, Inc. and Wilson Therapeutics AB announced today that Alexion has made a recommended public cash offer to the shareholders in Wilson Therapeutics to acquire all outstanding shares in Wilson Therapeutics by way of a tender offer, through a wholly-owned subsidiary.

  • 4 Biotech Stocks With Leaky Pipelines
    InvestorPlace11 days ago

    4 Biotech Stocks With Leaky Pipelines

    When it comes to biotech stocks, a pipeline can make or break a company. Due to the nature of the clinical trial system, a company can work for years on a new drug only to have all that work disappear when a therapy is found unsafe and ineffective. After a given amount of time, any company can produce a generic version of the drug a biotech company spent millions developing and have come to depend on revenue-wise.

  • Thomson Reuters StreetEvents11 days ago

    Edited Transcript of ALXN presentation 7-Mar-17 6:05pm GMT

    Alexion Pharmaceuticals Inc at Raymond James Institutional Investors Conference

  • See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.
    Markit11 days ago

    See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.

    This could indicate that investors who seek to profit from falling equity prices are not currently targeting ALXN. Over the last one-month, outflows of investor capital in ETFs holding ALXN totaled $14.43 billion.

  • NYSE trader: Here's why stocks are up and headline risk is down
    Yahoo Finance Video3 days ago

    NYSE trader: Here's why stocks are up and headline risk is down

    Keith Bliss of Cuttone and Company joins Yahoo Finance's Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.